Patents Assigned to Quest Diagnostics
  • Mass spectrometry method for measuring thiamine in body fluid
    Patent number: 10738344
    Abstract: Provided are methods for determining the amount of total thiamine in a body fluid sample using liquid chromatography and mass spectrometry. Total thiamine is converted to free thiamine by treatment with an acid phosphatase prior to thiamine separation and quantification.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: August 11, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Sum Chan, Qibo Jiang, Richard E. Reitz
  • BCR-ABL variants
    Patent number: 10739345
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: August 11, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Maher Albitar
  • Molecular detection of enterovirus and parechovirus
    Patent number: 10724111
    Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: July 28, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
  • Thyroglobulin quantitation by mass spectroscopy
    Patent number: 10718779
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Kisspeptin-54 detection by tandem mass spectrometry
    Patent number: 10712348
    Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory E. Bystrom, Richard E. Reitz
  • Methods for detecting lacosamide by mass spectrometry
    Patent number: 10712319
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • CANCER DIAGNOSIS USING KI-67
    Publication number: 20200209242
    Abstract: The present invention provides methods and compositions for detection, diagnosis, prognosis, monitoring treatment and monitoring progression of cancer by detecting the level of Ki-67 protein in an individual.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 2, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Jean Marie Bruey, Maher Albitar
  • Mass spectrometry assay for congenital adrenal hyperplasia
    Patent number: 10697980
    Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 30, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amit Ghoshal, Nigel J. Clarke, Mildred M. Goldman
  • Amplification and detection of nucleic acids in a biological sample
    Patent number: 10697002
    Abstract: Disclosed are methods for identifying the presence or absence of a target nucleic acid from one or more organisms in a biological sample, said method comprising: (a) spinning the sample at a rotational velocity sufficient to pellet cellular debris and fluorescence inhibitors present within the sample and reduce fluorescence interference or quenching in the sample; and (b) directly amplifying and detecting the target nucleic acid in the sample.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 30, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Lucien Jacky, Albert Castro, Peter Lee, Jose Matud, Michelle Tabb
  • Methods for screening solid tumors for mutations
    Patent number: 10689710
    Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 23, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Kevin Qu, James Prentice, Frederic Waldman
  • METHODS FOR DETECTING GENE DYSREGULATION BY INTRAGENIC DIFFERENTIAL EXPRESSION
    Publication number: 20200181718
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 11, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Methods of detecting reverse triiodothyronine by mass spectrometry
    Patent number: 10672600
    Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: June 2, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: J. Fred Banks, Peter P. Chou, Noriya M. Matt
  • Diagnosis of prostate cancer
    Patent number: 10669536
    Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 2, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Heather R. Sanders
  • RNA ISOLATION FROM SOLUBLE URINE FRACTIONS
    Publication number: 20200157527
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 21, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li
  • Cystic fibrosis transmembrane conductance regulator gene mutations
    Patent number: 10655179
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 19, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Feras Hantash
  • Diagnostic and prognostic assays based on circulating tyrosine kinase activity
    Patent number: 10655161
    Abstract: Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 19, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Chen-Hsiung Yeh
  • Quantitation of insulin-like growth factor-I and insulin-like growth factor-II with high-resolution mass spectrometry
    Patent number: 10648989
    Abstract: Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 12, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory Bystrom, Shijun Sheng, Nigel Clarke, Richard E. Reitz
  • DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN BIOLOGICAL SAMPLES
    Publication number: 20200140929
    Abstract: Discloses are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.
    Type: Application
    Filed: August 19, 2019
    Publication date: May 7, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Lakshmi Nair, Heather Vincent, Huong Mai, Michelle Tabb, Maurice Exner
  • PROGNOSTIC ASSAYS FOR MAINTENANCE HEMODIALYSIS PATIENTS
    Publication number: 20200132702
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Applicants: Quest Diagnostics Investments LLC, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    Inventors: Kamyar Kalantar-Zedeh, Michael P. Caulfield, Wael A. Salameh
  • EML4-ALK TRANSLOCATIONS IN LUNG CANCER
    Publication number: 20200123617
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 23, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig